Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case
Authors:
- 17 November 2013
- journal article
- case report
- Published by Springer Nature in Surgery Today
- Vol. 44 (10) , 1957-1961
Abstract
We monitored serum p53 antibody (s-p53-Ab) titers in a 76-year-old man with esophageal adenocarcinoma, clinical stage III (T2N2M0), for over 4 years, including during the perioperative period and throughout follow-up after surgery. Screening tests for CA19-9 (205 IU/ml) and s-p53-Abs (381 U/ml) were positive before treatment. After neoadjuvant chemotherapy with 5-FU and cisplatin, CA19-9 decreased to the normal range, but the s-p53-Ab titer remained positive (224 U/ml). Pathological findings of surgically resected specimens showed stage T1b disease and no lymph node metastases. After surgery, s-p53-Ab titers consistently decreased, with no disease recurrence. Although the s-p53-Ab titer remained positive even after 4 years, it decreased to 8.66, 3.59, 2.38, and 1.92 U/ml, 1, 2, 3, and 4 years after surgery, respectively. Thus, monitoring perioperative changes in s-p53-Ab titers proved useful for detecting the presence of residual cancer cells in a patient with superficial esophageal adenocarcinoma.Keywords
This publication has 21 references indexed in Scilit:
- Impact of serum biomarkers on esophageal squamous cell carcinomaEsophagus, 2012
- Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patientsSurgery Today, 2011
- Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective studyEuropean Journal of Cardio-Thoracic Surgery, 2010
- Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinomaWorld Journal of Gastroenterology, 2008
- Molecular diagnosis and treatment for esophageal carcinoma with p53Esophagus, 2007
- Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinomaDiseases of the Esophagus, 2007
- Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patientsGastric Cancer, 2005
- Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapyInternational Journal of Colorectal Disease, 2004
- Titration of serum p53 antibodies in 1085 patients with various types of malignant tumorsCancer, 2003
- Clinical implications of serum anti-p53 antibodies for patients with gastric carcinomaCancer, 1999